**Management of Life-threatening Bleeding in Anticoagulated Patients**

**Supportive Care**
- Hemodynamic support
- ICP management
- Blood product transfusion
- Transfer for tertiary care

Uncertain anticoagulation status

- **4FPCC:** 25-50 IU/kg
- **IV vitamin K:** 10 mg

Life-threatening bleeding

- **Warfarin**
- **Idarucizumab:** 5 g IV
- **Dabigatran**
- **Factor Xa Inhibitor**

Andexanet alpha
If prolonged delay to andexanet or idarucizumab consider 4FPCC or FFP

≥ 8 hrs from last dose
- Rivaroxaban ≤10 mg
  - Apixaban ≤5 mg
  - **Low dose andexanet alpha**
    - Initial IV bolus: 400 mg at 30 mg/min
    - Follow-on IV infusion: 4 mg/min up to 120 min

< 8 hrs from last dose
- Rivaroxaban >10 mg
  - Apixaban >5 mg
  - **High dose andexanet alpha**
    - Initial IV bolus: 800 mg at 30 mg/min
    - Follow-on IV infusion: 8 mg/min up to 120 min

* Life-threatening bleeding including intracerebral hemorrhage and exsanguinating gastrointestinal bleeding.
** FDA approved for rivaroxaban and apixaban only, but mechanism of action suggests it may be equally effective for edoxaban and betrixaban.
ICP, intracranial pressure; 4FPCC, four-factor prothrombin complex concentrate; DOAC, direct oral anticoagulant.